ClinicalTrials.gg
Active, not recruitingNCT04992104MMIPUpdated Apr 28, 2026

Microbiome and Malnutrition in Pregnancy

An observational study in Pregnancy Related, Pregnancy Loss and Pregnancy Complications, sponsored by The Hospital for Sick Children. Active, not recruiting at 2 sites in Canada. Open to female participants aged Up to 28 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by The Hospital for Sick Children · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
Up to 28 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Pregnancy Complications with a site in Canada — 5 open to participants now, 11 under way, none of them phase 3. Pregnancy Complications · Canada.

Started
2023
with 2 others
Observational
9 of 24
2 open now
Primary completion
2027-03
later than 8 of 10 live
Registered
17th of 24
by date
Lead sponsor
2 of 24
The Hospital for Sick Children

Among the 24 studies in Pregnancy Complications with a site in Canada, this one is one of 3 that started in 2023, is one of 9 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 17th registered.

Pregnancy Complications

411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.

Browse Pregnancy Complications studies →

Open to participants now

5 of the 24 studies in Pregnancy Complications with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.

This study: Up to 28 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pregnancy Complications with a site in Canada, or all of them as a file.
02

Study summary

This study is being conducted to investigate how a mother's nutritional status and her gut microbiome during pregnancy contribute to the birth outcomes and health of her baby. The gut microbiome is the totality of microorganisms (e.g. bacteria, viruses, fungi) living in the gastrointestinal tract. This study will focus on pregnant women, 28 years and younger living in the Toronto and greater Toronto area. The focus is on younger women due to their vulnerability to undernutrition. Pregnant participants, and upon delivery, their newborns will be followed throughout pregnancy and for a year afterwards. Throughout this period, the investigators will collect stool samples, rectal swabs, blood samples, health assessments, nutritional and dietary assessments and birth/ labour details. The goal is to define the relationship between a mother's nutritional status and her microbiome dynamics during pregnancy and how they contribute to the birth outcomes and growth of her newborn. With the hypothesis that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.

Read the detailed description

This project represents the first systematic investigation of the impact of the microbiome on nutritional status during pregnancy in young women and directly aligns with global health initiatives focused on this vulnerable cohort. The goal of the study is to define the relationships between host nutritional status and microbiome dynamics during pregnancy and how they contribute to birth outcomes. The gut microbiome has a profound influence on host nutritional status. Dysbiosis (loss of diversity/beneficial microbes and gain of pathobionts) has emerged as a major factor in the development of undernutrition. Despite the importance of nutrition during pregnancy, few studies have examined the role of the microbiome on maternal health and birth outcomes. Further, little is known concerning the influence of enteric eukaryotic microbes, such as parasites, on the bacterial microbiome and host nutrition.

At the core of this study are two complementary cohorts of young women that provide an exceptional opportunity to obtain longitudinal samples to monitor the dynamic relationships between microbiome community structure and function with gut health and host nutritional status. This registration is for the the Toronto cohort of the study, which will focus on refugee and young adult obstetric clinics in Toronto, a population of specific relevance to undernutrition. This cohort is expected to yield insights into the influence of eukaryotic microbes that are often viewed as asymptomatic. The target demographic of the study is young mothers, 28 years of age and younger, in the Toronto and Greater Toronto Area. The investigators have identified this younger demographic due to the lack of knowledge on the microbiome of young women, and their vulnerability to undernutrition. A second complementary cohort will be based in the Matiari district of Pakistan. This project will yield unprecedented insights into the relationships between prokaryotic and eukaryotic microbes in the gut and their associations with maternal health and birth outcomes.

The central hypothesis of the study is that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.

The study will be a prospective, longitudinal, observational study to investigate the impact and relationship between prokaryotic and eukaryotic microbes in the gut and their association with maternal health and birth outcomes among young women, 28 years of age and younger in the Toronto and Greater Toronto Area. The study will aim to recruit 400 women into two groups based on BMI at time of recruitment (Normal BMI will be defined as between 20 and 24.9 kg/m2 and Low BMI will be defined as less than 20 kg/m2). With a goal of having 200 participants within the normal BMI group and 200 participants within the low BMI group. Although this is the recruitment aim, in the event that the investigators are unable to recruit 200 women with a low BMI, more women will be recruited that fall within the normal BMI range. The study will follow women and their infants over the course of their pregnancy and for a year post-partum, collecting stool, rectal and blood samples, nutritional information, heath assessments, anthropometric measurements and empowerment metrics at different time points.

03

Conditions studied

  • Pregnancy Related
  • Pregnancy Loss
  • Pregnancy Complications
  • Pregnancy; Parasitic Disease
  • Microbial Colonization
  • Microbial Disease
  • Parasitic Disease
  • Metabolomics
  • Malnutrition
  • Malnutrition, Infant
  • Malnutrition Pregnancy
  • Breast Feeding
04

Who can participate

Ages eligible
Up to 28 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of pregnant women, 28 years of age and younger, living in the Toronto and Greater Toronto Area. The investigators focus on younger women, due to the lack of knowledge about their microbiome and their vulnerability to undernutrition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Consent provided
  2. Participant is between 8-20 weeks post-conception
  3. Female aged 28 years of age and younger
  4. Confirmation of pregnancy
  5. Intend to comply with study procedures and follow up

Exclusion criteria

Exclusion Criteria:

  1. Women who do not meet the enrolment age criteria
  2. Women who are 20 + weeks post-conception
  3. Women who have taken antibiotics within the past 3 months Note: it is common practice to give the mother penicillin in perinatal period if they are GBS positive; because this is standardized across the board it would not act as an exclusion factor.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. To assess if alterations of the microbiota in the maternal gut (dysbiosis) are associated with changes in maternal gestational weight gain.

    The primary endpoint will be the change in maternal gestational weight gain (GWG) during pregnancy, measured between the first (8-20 weeks post-conception) and second time point (30-34 weeks post conception).

    Time frame: 8-20 weeks post-conception, 30-34 weeks post conception

Secondary outcomes

  1. Anthropometrics: Maternal BMI

    calculated using weight and height; BMI = kg/m2

    Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum

  2. Anthropometrics: Maternal middle upper arm circumference

    Measured in cm

    Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum,and 12 months post-partum

  3. Anthropometrics: Maternal triceps skinfold thickness

    Measured in cm

    Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum, and 12 months post-partum

  4. Anthropometrics: Maternal height

    Measured in cm

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post partum

  5. Anthropometrics: Maternal weight

    Measured in kg

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post-partum

  6. Maternal blood biomarkers

    Concentration of HB + MCV, ferritin, and CRP

    Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, and 12 months post-partum

  7. Infant blood biomarkers

    Concentration of HB + MCV, ferritin, and CRP

    Time frame: 12 months

  8. Infant sex

    Female or Male

    Time frame: Determined at delivery

  9. Infant morbidity

    Assessed through infant health assessment questionnaires

    Time frame: 3 months, 6 months and 12 months

  10. Maternal morbidity

    Assessed through health assessment questionnaires

    Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, 3 months post-partum, 6 months post-partum and 12 months post-partum

  11. Infant growth: weight

    Measured in kg

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  12. Infant growth: length

    Measured in cm

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  13. Infant growth: head circumference

    Measured in cm

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  14. Infant growth: mid upper arm circumference

    Measured in cm

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  15. Infant growth: triceps skinfold thickness

    Measured in cm

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  16. Infant Gestational age

    Will be documented at baseline visit.

    Time frame: 8-20 weeks post conception

  17. Breast feeding: amount and initiation of complementary feeding

    Based off of WHO 2010 Guidelines: Indicators for assessing infant and young child feeding practices (Part 2 Measurement)

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  18. Maternal age

    28 years or younger

    Time frame: Documented at 8-20 weeks post-conception

  19. Reported maternal medication use

    \[Questionnaire\]

    Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, within 24 hours of delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum

  20. Reported Infant medication use

    \[Questionnaire\]

    Time frame: within 24 hours of birth, 3 months, 6 months and 12 months

  21. Maternal dietary intake

    Assessed through ASA 24 HR Dietary Recall system, completed 2x each time point

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception and 12 months post partum

  22. Dietary diversity

    Minimum Dietary Diversity Score for Women (MDD-W)

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post-partum and 12 months post partum

  23. Household annual food insecurity

    Food insecurity will be assessed using the Household Food Insecurity Access Scale (HFIAS)

    Time frame: 3 months post-partum and 12 months post-partum

  24. Self-efficacy

    Self-efficacy will be measured using the Generalized Self-Efficacy scale, developed by Schwarzer and Jerusalem

    Time frame: 3 months post-partum and 12 months post partum

  25. Perceived decision making

    Questions pertaining to perceived decision-making are from the Pakistan Demographic and Health Survey (PDHS)

    Time frame: 3 months post-partum and 12 months post partum

  26. Perceived social support

    Perceived social support will be measured using the Multi-dimensional Scale of Perceived Social Support (MSPSS), developed by Zimet et al.

    Time frame: 3 months post-partum and 12 months post partum

  27. Maternal demographics

    Questions pertaining to demographic data are adapted from the Pakistan Demographic and Health Survey (PDHS)

    Time frame: 8-20 weeks post-conception

  28. Food insecurity

    Questionnaire developed by Hager, E.R., et al., Development and validity of a 2-item screen to identify families at risk for food insecurity.

    Time frame: 8-20 weeks post conception, 3 months post partum and 12 months post partum

  29. Perceived parental stress

    Perceived parental stress will be measured using the Perceived Stress Scale (PSS-10)

    Time frame: 3 months post-partum and 12 months post partum

  30. Preterm birth

    noted in labor and birth chart review

    Time frame: Within 24 hours of birth

  31. Stillbirth

    noted in labor and birth chart review

    Time frame: Within 24 hours of birth

  32. Small for gestational age

    noted in labor and birth chart review

    Time frame: Within 24 hours of birth

  33. Large for gestational age

    noted in labor and birth chart review

    Time frame: Within 24 hours of birth

  34. Birth size: length

    Measured in cm

    Time frame: within 24 hours of birth

  35. Birth size: head circumference

    Measured in cm

    Time frame: within 24 hours of birth

  36. Birth size: weight

    Measured in kg

    Time frame: within 24 hours of birth

  37. Birth defects

    Assessed within 24 hours of birth

    Time frame: within 24 hours of birth

  38. Delivery assessment

    Assessed within 24 hours of birth

    Time frame: within 24 hours of birth

  39. Infant dietary intake: NutricheQ Questionnaire

    NutricheQ questionnaire: a tool designed for toddlers aged 1 to 3 years of age, with a focus on markers for inadequate or excessive intake and dietary imbalances

    Time frame: 12 months

  40. Maternal stool biomarkers: Calprotectin, Lipocalin and Claudin 15

    Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  41. Infant Stool biomarkers: Calprotectin, Lipocalin and Claudin 15

    Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers

    Time frame: 3 months and 12 months

  42. Maternal: incidence of pathobionts

    As identified through 16S, 18S and ITS rDNA surveys

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  43. Infant: incidence of pathobionts

    As identified through 16S, 18S and ITS rDNA surveys

    Time frame: 3 months and 12 months

  44. Maternal: metabolomic profile of stool (metabolites involved in central metabolism as analysed by Mass Spectrometry)

    Analysis of the core metabolites involved in central metabolism. These metabolites will be analysed through Mass Spec and include short chain fatty acids, amino acids, intermediates in energy metabolism and nucleotide biosynthesis

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  45. Maternal gut bacteria profile as measured through 16S rDNA sequence surveys

    measured through 16S rDNA sequence surveys

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  46. Maternal: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25)

    TMIC Metallomics Platform to be used.

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, and 12 months post partum

  47. Infant: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25)

    Through TMIC platform

    Time frame: 12 months

  48. Infant: gut bacterial profile as measured through 16S rDNA sequence surveys

    measured through 16S rDNA sequence surveys

    Time frame: 3 and 12 months post partum

  49. Maternal metabolic pathway expression profile as measured through whole microbiome RNASeq (metatranscriptomics)

    measured through whole microbiome RNASeq (metatranscriptomics)

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  50. Infant eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys

    measured through 18S and ITS rDNA sequence surveys

    Time frame: 3 months and 12 months

  51. Maternal eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys

    measured through 18S and ITS rDNA sequence surveys

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  52. Maternal bacterial gene expression profile as measured through whole microbiome RNASeq (metatranscriptomics)

    The output of these analyses are readouts of microbial gene expression detailing biochemical activities as well as the taxa responsible.

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  53. Maternal: microbiome taxonomic alpha and beta diversity

    To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances.

    Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum

  54. Infant: microbiome taxonomic alpha and beta diversity

    To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances.

    Time frame: 3 months and 12 months

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In addition to publishing findings in open access journals, the investigators will ensure all sequences and metabolomics datasets are deposited in appropriate public repositories. SOPs, pathogen samples and statistical methods developed through this project will be shared with the IMPACTT research core (https://www.impactt-microbiome.ca/). Microbiome sequence data will be uploaded on the National Centre for Biotechnology Information (NCBI). The NCBI acts as a central data repository for sequence data. In line with publication standards, the investigators are required to provide access to users who may wish to follow up on analyzing the microbiome data for their own purposes. The sample analysis information, including the sequencing data and metabolomics data will be de-identified and the patient sequence data will be removed.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: All sequence and metabolomics data will be made available within 12 months of study completion Supporting information will be shared at time of request

Access criteria: Supporting information will be shared upon request Sequence and metabolomics datasets will be made available without restriction

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.

Of 113 non-industry observational studies under Pregnancy Complications, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 201. This study's planned 49 months is below that.

Counting every sponsor, half of 121 studies reached it within 60 months; a quarter within 30 and three quarters within 201.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Aug 5, 2021
StartActual
Feb 22, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04992104
Responsible party
John Parkinson (Senior Scientist, The Hospital for Sick Children) — Principal investigator
First posted
Aug 5, 2021
Start date
Feb 22, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

John Parkinson, PHD
principal investigator · The Hospital for Sick Children
Shazeen Suleman, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion